Drugs / C1-esteraseremmer-N
C1-esteraseremmer-N
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00125541 | Nov 2006 → Apr 2008 | angioedema | Prothya Biosolutions | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00125151 | Feb 2006 → Apr 2007 | angioedema | Prothya Biosolutions | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C1-esteraseremmer-N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00125151 ↗ |
| Known as | C1 inhibitor concentrate | “C1 inhibitor concentrate (C1-esteraseremmer-N)” NCT00125151 ↗ |
| Known as | Cetor | “A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the...” NCT00125541 ↗1“nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase)” NCT00125151 ↗ |
| Action | Inhibit | “C1 inhibitor concentrate” NCT00125541 ↗ |
| Modality | Protein / enzyme biologic | “C1 inhibitor concentrate (C1-esteraseremmer-N)” NCT00125541 ↗ |